Share This
Description
Cancer care is undergoing a shift from a 'one-size-fits all' approach to more personalised medicine. One way of personalising cancer treatments is through biomarkers: molecules or biochemical changes found in the patient's tissues and body fluids.
This book reflects upon the promise of cancer biomarkers and asks questions such as: How may the complexity of cancer biology impede the robustness of biomarkers in the clinic? How should one draw the line between the various sub-groups of patients for personalised treatment? How can one evaluate the cost-effectiveness and fairness of personalised cancer treatments? By bringing together authors from the fields of science and technology studies, medical ethics and philosophy, health economics and oncology, the book aims to give a critical yet accessible overview of some of the key social, ethical and economic issues that surround cancer biomarkers.
"The book should be required reading for oncologists, medical students, graduate students and especially for those who make policy decisions regarding the use and reimbursement of cancer biomarkers." - Bruce Zetter, Charles Nowiszewski Professor of Cancer Biology in the Department of Surgery, Harvard Medical School
Tag This Book
This Book Has Been Tagged
Our Recommendation
Notify Me When The Price...
Log In to track this book on eReaderIQ.
Track These Authors
Log In to track Alessandro Blasimme on eReaderIQ.
Log In to track Anne Blanchard on eReaderIQ.
Log In to track Caroline Engen on eReaderIQ.
Log In to track Eirik Tranvåg on eReaderIQ.
Log In to track Elisabeth Wik on eReaderIQ.
Log In to track John Cairns on eReaderIQ.
Log In to track Leonard M. Fleck on eReaderIQ.
Log In to track Mikyung Kelly Seo on eReaderIQ.
Log In to track Ole Frithjof Norheim on eReaderIQ.
Log In to track Roger Strand on eReaderIQ.